Prakash V Diwan, male Pharmacologist, obtained his PhD from Post graduate Institute of Medical Education and Research, India in 1980. He served as Assistant Professor in Medical College, India and later joined the Research and development organization, Indian Institute of Chemical Technology (CSIR) in 1983-2007. He became the Founder Director NIPER, Hyderabad in the year 2007. He was awarded with many national awards in the field of pharmacology. He is a Fellow of Royal Society of London (FRSC). To his credit he has over 160 research publication in national and international journals. He has been honored as a fellow of Indian Pharmacological Society and fellow of Andhra Pradesh Academy of Sciences. He has been a member in Indian Pharmacopeia Commission, Scientific Consultant for various reputed pharmaceutical industries. Presently he holds the responsible positions as Director and Research scientist in academia & Research and development Institutions.

pharmacology,biostatistics, bio standardization and Toxicology

He is completed his Postdoctoral Scholar at University of California, San Dieg and Graduate Research Assistant in University of Illinois at Urbana-Champaign. Now he is a Research Scientist in University of California, San Diego.

Molecular Biology, Cellular Biology, Biochemistry, and Microscopy Techniques

Dr Sergey Suchkov, MD, PhD. Professor in Immunology & Medicine. Chair, Dept for Personal-ized and Translational Medicine, I.M.Sechenov First Moscow State Medical Born 11 January 1957, Astrakhan, Russia; two sons. Education: MD, Astrakhan State Medical University, Russia, 1980; PhD, I.M.Sechenov First Moscow State Medical University, 1985; Doctor Degree, Na-tional Institute of Immunology, Russia, 2001. Positions held: Post Doc Research Associate, In-stitute of Medical Enzymology; Head of the Lab of Immunology, Helmholtz Eye Research Insti-tute in Moscow; Trainee, Laboratory of Immunology, NEI, Bethesda, MD, USA; Chair,, De-partment for Clinical Immunology, Moscow Clinical Research Institute; Executive Secretary-in-Chief of the Editorial Board, Biomedical Science International journal; Chairman & Director of the Department of Personalized Medicine. Honours: Secretary General, United Cultural Conven-tion, Cambridge, UK. Memberships: New York Academy of Sciences, USA; EPMA, Brussels.

Abs against myelin basic protein/MBP endowing with proteolytic activity (Ab-proteases) are of great value to monitor demyelination to illustrate the evolution of multiple sclerosis (MS). Anti-MBP autoAbs from MS patients and mice with EAE exhibited specific proteolytic cleavage of MBP The activity of the MBP-targeted Ab-proteases markedly differs between: (i) MS patients and healthy controls; (ii) different clinical MS courses; (iii) EDSS scales of demyelination to cor-relate with the disability of MS patients to predict the transformation prior to changes of the clin-ical course. The sequence-specificity of Ab-proteases demonstrates five sites of preferential proteolysis to be located within the immunodominant regions of MBP confirmed by the structural databanks. Two of them falling inside the sequence covering a 81-103 peptide and its 82-98 subsegment as well, with the highest encephalitogenic properties both to act as a specific inducer of EAE and to be attacked by the MBP-targeted Ab-proteases in MS patients with the most severe (progradient) clinical courses. Sites localized within the frame of 43-68 and 146-170 peptide subsegments whilst being less immunogenic happened to be EAE inducers very rare but were shown to be attacked by Ab-proteases in MS patients with moderate (remission-type) clinical courses. The activity of Ab-proteases was first registered at the subclinical stages 1-2 years prior to the clinical illness. About 24% of the direct MS-related relatives were seropositive for low-active Ab-proteases from which 38% of the seropositive relatives established were being monitored for 2 years whilst demonstrating a stable growth of the Ab-associated proteolytic activity. Registration in the evolution of highly immunogenic Ab-proteases to attack 81-103 and 82-98 sites pre-dominantly would illustrate either risks of transformation of subclinical stages into clinical ones, or risks of exacerbations to develop. The activity of Ab-proteases in combination with the sequence-specificity would confirm a high subclinical and predictive (translational) value of the tools as applicable for personalized moni-toring protocols. And close association between the proteolytic sensitivity of MBP and post-translational modifications of the latter may represent one of the key regulatory mechanisms in the epitope generation.

She is a Postdoctoral Fellow in Proteomics The University of Durham, Durham, UK and Research Associate (Funded by BBSRC and SABMiller)in Department of Molecular Biology and Biotechnology at University of Sheffield, United Kingdom.

Mahsa Movahedi had 7 years of research experience in understanding cellular mechanisms, and proteomics, with a background in molecular biology and biochemistry research. She is an expert in experimental design, data analysis, and project management.

He is a Postdoctoral Fellow at University of Oxford, Oxford, UK and Visiting Professor in Pohang University of Science and Technology (POSTECH), South Korea.Gajendra Raghava is a Bioinformatics Specialist at University of Arkansas for Medical Sciences (UAMS), USA.Scientist at CSIR-Institute of Microbial Technology, India.

bioinformatician, life sciences, biophysics, Microbial Technology.

Dr. George Perry received his PhD in Marine Biology from Scripps Institution of Oceanography, University of California at San Diego. He completed his Postdoctoral Fellowship in the Department of Cell Biology, Baylor College of Medicine, Houston, Texas.Dr. Perry joined the UTSA faculty in 2006 from Case Western Reserve University where he was Professor of Pathology and Neurosciences and Chair of the Department of Pathology. He is also distinguished as one of the top 20 Alzheimers disease researchers with over 800 publications, one of the top 100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in Free Radical research . He currently serves as and President for the American Association of Neuropathologists. He is on the editorial board of over 60 journals including American Journal of Pathology and Journal of Biological Chemistry, and is Editor-in-Chief of Journal of Alzheimer’s Disease.

Mechanism for RNA-based redox metal binding consequences of RNA oxidation on protein synthesis rate and fidelity role of redox active metals in mediating prooxidant and antioxidant properties signal transduction pathways altered in Alzheimer disease that allow neurons to evade apoptosis mechanism of phosphorylation control of oxidative damage to neurofilament proteins.

Plato is a Associate Professor at University of Patras, Greece and also Adjunct Professor at New York University, USA. He is a Rersearch Fellow at Merck Research Laboratories, Rahway, New Jersey, USA.Postdoctoral Fellow ; Harvard University, USA; Ph.D. in Chemical Biology; SUNY at Stony Brook, USA.

Synthesis of biologically and pharmacologically relevant molecules such as a- and b-amino acids, b-lactams, piperidines, and piperazines. Total Synthesis of antitumor, antibiotic Natural Products (Cyclostreptin-(-)-FR182877, Ecteinascidin 743, Saframycin A, and Abyssomicin C). New Synthetic Methodology including novel routes to b-lactams, piperazines and tetrasubstituted olefins (Tamoxifen analogs).

Dr. Luo is a member of the Divisions of Experimental Pathology, Molecular and Cellular Pathology and Anatomic Molecular Pathology. He is the Director of the High Throughput Genome Center at the Department of Pathology, University of Pittsburgh, involving collaboration of faculties from multiple departments.

Currently, Dr. Luo's research interests involve identifying new tumor suppressor genes and tumor markers in several human malignancies such as prostate cancer, hepatocellular carcinoma, etc. Subsequently, we will direct our effort to evaluate the prognostic values of these genes and markers in making early diagnosis of prostate cancer and serving as drug targets for cancer prevention programs.

Rosemarie Wahl, Ph.D., earned a BS degree in Quantitative Biology from MIT, a MS degree in Biochemistry and a Ph.D. in Microbiology from the University of Chicago. She has been a faculty member at the University of Illinois at Chicago Circle, Texas Christian University, the University of Texas at Austin and St. Mary’s University. She was Chair of the Department of Biological Sciences at St. Mary’s University for 25 years (1979-2004), and is currently Professor of Biology.

Her research contributions are in the molecular structure of bacterial viruses, the chemical basis of genetic mutation and the mechanism of DNA replication.

Dr. Vo-Dinh is R. Eugene and Susie E. Goodson Distinguished Professor of Biomedical Engineering, Professor of Chemistry, and Director of the Fitzpatrick Institute for Photonics at Duke University. After completing high school in Vietnam, he pursued his education in Europe where he received a B.S. in physics in 1970 from EPFL (Swiss Federal Institute of Technology) in Lausanne, Switzerland, and a Ph.D. in physical chemistry in 1975 from ETH (Swiss Federal Institute of Technology) in Zurich, Switzerland. Before joining Duke University in 2006, Dr. Vo-Dinh was Director of the Center for Advanced Biomedical Photonics, Group Leader of Advanced Biomedical Science and Technology Group, and a Corporate Fellow, one of the highest honors for distinguished scientists at Oak Ridge National Laboratory (ORNL). His research has focused on the development of advanced technologies for the protection of the environment and the improvement of human health. His research activities involve nanophotonics, biophotonics, nano-biosensors, biochips, molecular spectroscopy, bioimaging for medical diagnostics and therapy (nano-theranostics), personalized medicine, and global health.

Dr. Vo-Dinh has authored over 400 publications in peer-reviewed scientific journals. He is the author of a textbook on spectroscopy and editor of 9 books. He holds over 37 U.S. and international patents, five of which have been licensed to private companies for commercial development. Dr. Vo Dinh has presented over 200 invited lectures at international meetings in universities and research institutions. He has chaired over 20 international conferences in his field of research and served on various national and international scientific committees.

Biography Biography Sivakumar’s research is primarily focused on biotech implications and applications of high-value natural products. He has extensively studied the plant-based small molecules pathway biochemistry, synthetic biology and metabolic & bioprocess engineering. He is internationally recognized in the field of biopharmaceuticals and a pioneer in industrial-scale production of bioactive molecules. He has over 40 publications. He is also on the editorial board of several journals. He serves as an expert of grant proposals as well as numerous scientific journals. His laboratory focuses on metabolic and bioprocess engineering of colchicine pathway and developing potential anticancer medicine. In addition, his group is interested in developing biofuels to address energy and environmental problems. Additional information can be found at http://tech.uh.edu/ganapathy

biotech implications and applications,molecules pathway biochemistry, synthetic biology and metabolic & bioprocess engineering

He is a Principal Investigator, School of Life Sciences, Tsinghua University, China

1. Investigate the pathogenesis of neurological disorders using induced pluripotent stem cell technology 2. Study the mechanisms underlying neurotransmitter release and synaptic vesicle cycling in the presynaptic nerve terminal using patch clamp recording and fluorescence imaging techniques 3. Investigate synaptic plasticity in neurological disorders and neural network formation